Eric Nuermberger, MD

Eric Nuermberger, M.D. is Associate Professor of Medicine and International Health at Johns Hopkins University. He has been involved in the development of new anti-tubercular agents since 2001. His research using in vitro and animal models of tuberculosis to optimize dosing of new and existing drugs and design optimal drug combinations has informed the clinical development of moxifloxacin, rifapentine, pretomanid, bedaquiline and sutezolid and the pre-clinical development of numerous other compounds. It is funded by the National Institutes of Health, the U.S. Food and Drug Administration, the Bill and Melinda Gates Foundation, the Global Alliance for TB Drug Development, and various pharmaceutical companies. Dr. Nuermberger is a member of the AIDS Clinical Trial Group’s TB Transformative Science Group and the Core Science Group of the TB Trials Consortium.  He is also Co-Chair of the Preclinical and Clinical Sciences Work Group of the Critical Path to TB Drug Regimens (CPTR) initiative. Dr. Nuermberger also serves as an Associate Editor of the Antimicrobial Agents and Chemotherapy and the International Journal of TB and Lung Disease.

  • Investigator, TB Transformative Science Group (Dec 2016)
  • Investigator, Protocol team A5279
  • Investigator, Protocol team A5356

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More